Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
Conditions
Brief summary
The trial is open to patients who have metastatic renal cell carcinoma/urothelial (bladder) carcinoma with at least 2 measurable sites of disease. All eligible patients will be randomly assigned to immunotherapy(nivolumab/atezolizumab/pembrolizumab) versus immunotherapy (nivolumab/atezolizumab/pembrolizumab) plus radiotherapy, 10 Gy x3 (conformally or by intensity modulation radiation therapy/Image-guided radiation therapy (IMRT/IGRT) to maximally spare normal tissue), to one of their measurable lesions.
Detailed description
The trial is open to patients who have metastatic renal cell carcinoma/urothelial (bladder) carcinoma with at least 2 measurable sites of disease. All eligible patients will be randomly assigned to immunotherapy(nivolumab/atezolizumab/pembrolizumab) versus immunotherapy (nivolumab/atezolizumab/pembrolizumab) plus radiotherapy, 10 Gy x3 (conformally or by IMRT/IGRT to maximally spare normal tissue), to one of their measurable lesions. For patients assigned to the immunotherapy plus radiotherapy arm, immunotherapy treatment starts with the first radiotherapy fraction. Nivolumab will be given every 2 weeks for patients with metastatic renal cell cancer and atezolizumab/pembrolizumab will be given every 3 weeks for patients with metastatic urothelial cancer. Patients will be re-imaged at 9 week (year 1) or 12 week (years 2-3) intervals and evaluated for response (defined as an objective response of measurable metastatic sites outside the radiation field). This response will be evaluated with CT scans in non-irradiated measurable metastatic sites per RECIST version 1.1. Patients will continue to receive their respective immunotherapies for up to three years or until disease progression or until a dose limiting toxicity is reached.
Interventions
DRUGNivolumab
Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
DRUGAtezolizumab
Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
RADIATIONRadiation & immunotherapy
Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
DRUGPembrolizumab
Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Sponsors
Weill Medical College of Cornell University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Ability to understand and the willingness to sign a written informed consent document; 2. Any prior therapy is permitted except prior therapy with PD1/PDL1 inhibitor. 3. Histologic diagnosis of metastatic renal cell carcinoma or urothelial cancer; 4. Patients must have at least 2 distinct measurable metastatic sites at least 1 cm or larger in their largest diameter per RECIST 1.1 5. Patients must have adequate organ and marrow function as defined by initial laboratory tests. 6. At least 2 weeks since last chemotherapy and 4 weeks since last immunotherapy treatment. 7. Performance status Eastern cooperative oncology group (ECOG) 0-1 8. Men and women, ages \> 18 years of age. 9. Life expectancy \> 3 months 10. Stable brain metastases for at least 4 weeks and not steroid dependent 11. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the study in such a manner that the risk of pregnancy is minimized. Should a woman become pregnant or suspect she is pregnant while she is enrolled in this study, she should inform her treating physician immediately.
Exclusion criteria
1. Patients having no lesions outside the field of radiation thus nullifying the ability to measure an abscopal effect; 2. Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix; 3. Autoimmune/auto inflammatory disease: Patients with a history of inflammatory bowel disease are excluded from this study as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], Systemic Lupus Erythematosus, autoimmune vasculitis \[e.g., Wegener's Granulomatosis\]; 4. Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea; 5. Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of PD-1/PDL-1 blocking antibody). 6. A history of prior treatment with PD-1/PDL-1blocking antibody; 7. Patients who have had immunotherapy within 4 weeks prior to entering the study. 8. Concomitant therapy with any of the following: interleukin -2 (IL-2), interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids; 9. Patients undergoing therapy with other investigational agents or other chemotherapy agents; 10. Women who: 1. are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after cessation of study drug, or 2. have a positive pregnancy test at baseline, or 3. are pregnant or breastfeeding 11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With Best Overall Response Rates of Immunotherapy Alone and of Immunotherapy Plus Radiotherapy (to a Single Metastatic Site). | from 96 weeks |
| Assess the Difference in Participants for the Best Overall Response Between the Two Groups, Immunotherapy Alone and of Immunotherapy Plus Radiotherapy(to a Single Metastatic Site). | from 96 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants With Progression Free Survival | from 96 weeks |
| Number of Participants Who Experienced Toxicities Related to Immunotherapy and Immunotherapy Plus Radiotherapy Treatment Groups | from 96 weeks |
| Participants Will be Measured for Overall Survival | from 96 weeks |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm A - Immunotherapy Alone Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.
Patients with Urothelial cancer will receive Atezolizumab or Pembrolizumab on Days 1, 22, 43 and 64.
Nivolumab: Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
Atezolizumab: Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Pembrolizumab: Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64. | 4 |
| Arm B - Radiation & Immunotherapy Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
Nivolumab: Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
Atezolizumab: Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Radiation & immunotherapy: Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1. | 2 |
| Total | 6 |
Baseline characteristics
| Characteristic | Arm A - Immunotherapy Alone | Arm B - Radiation & Immunotherapy | Total |
|---|---|---|---|
| Age, Continuous | 56.25 years | 69 years | 60.5 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 0 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 2 Participants |
| Region of Enrollment United States | 4 participants | 2 participants | 6 participants |
| Sex: Female, Male Female | 1 Participants | 1 Participants | 2 Participants |
| Sex: Female, Male Male | 3 Participants | 1 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 2 |
| other Total, other adverse events | 1 / 4 | 1 / 2 |
| serious Total, serious adverse events | 1 / 4 | 1 / 2 |
Outcome results
Primary
Assess the Difference in Participants for the Best Overall Response Between the Two Groups, Immunotherapy Alone and of Immunotherapy Plus Radiotherapy(to a Single Metastatic Site).
Time frame: from 96 weeks
Population: 3 participants on ARM A and 2 participants on ARM B could not be analyzed because they were withdrawn from the trial for disease progression.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A - Immunotherapy Alone | Assess the Difference in Participants for the Best Overall Response Between the Two Groups, Immunotherapy Alone and of Immunotherapy Plus Radiotherapy(to a Single Metastatic Site). | 1 Participants |
| Arm B - Radiation & Immunotherapy | Assess the Difference in Participants for the Best Overall Response Between the Two Groups, Immunotherapy Alone and of Immunotherapy Plus Radiotherapy(to a Single Metastatic Site). | 0 Participants |
Primary
Number of Participants With Best Overall Response Rates of Immunotherapy Alone and of Immunotherapy Plus Radiotherapy (to a Single Metastatic Site).
Time frame: from 96 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A - Immunotherapy Alone | Number of Participants With Best Overall Response Rates of Immunotherapy Alone and of Immunotherapy Plus Radiotherapy (to a Single Metastatic Site). | 4 Participants |
| Arm B - Radiation & Immunotherapy | Number of Participants With Best Overall Response Rates of Immunotherapy Alone and of Immunotherapy Plus Radiotherapy (to a Single Metastatic Site). | 2 Participants |
Secondary
Number of Participants Who Experienced Toxicities Related to Immunotherapy and Immunotherapy Plus Radiotherapy Treatment Groups
Time frame: from 96 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A - Immunotherapy Alone | Number of Participants Who Experienced Toxicities Related to Immunotherapy and Immunotherapy Plus Radiotherapy Treatment Groups | 1 Participants |
| Arm B - Radiation & Immunotherapy | Number of Participants Who Experienced Toxicities Related to Immunotherapy and Immunotherapy Plus Radiotherapy Treatment Groups | 1 Participants |
Secondary
Number of Participants With Progression Free Survival
Time frame: from 96 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A - Immunotherapy Alone | Number of Participants With Progression Free Survival | 1 Participants |
| Arm B - Radiation & Immunotherapy | Number of Participants With Progression Free Survival | 0 Participants |
Secondary
Participants Will be Measured for Overall Survival
Time frame: from 96 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A - Immunotherapy Alone | Participants Will be Measured for Overall Survival | 4 Participants |
| Arm B - Radiation & Immunotherapy | Participants Will be Measured for Overall Survival | 2 Participants |